NDC 68682-003

bexarotene

Bexarotene

bexarotene is a Oral Capsule, Liquid Filled in the Human Prescription Drug category. It is labeled and distributed by Oceanside Pharmaceuticals. The primary component is Bexarotene.

Product ID68682-003_22590cf5-85a5-4129-a313-2e1cb2aba25d
NDC68682-003
Product TypeHuman Prescription Drug
Proprietary Namebexarotene
Generic NameBexarotene
Dosage FormCapsule, Liquid Filled
Route of AdministrationORAL
Marketing Start Date2015-12-17
Marketing CategoryNDA AUTHORIZED GENERIC / NDA AUTHORIZED GENERIC
Application NumberNDA021055
Labeler NameOceanside Pharmaceuticals
Substance NameBEXAROTENE
Active Ingredient Strength75 mg/1
Pharm ClassesRetinoid [EPC],Retinoids [CS]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 68682-003-10

1 BOTTLE in 1 CARTON (68682-003-10) > 100 CAPSULE, LIQUID FILLED in 1 BOTTLE
Marketing Start Date2015-12-17
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 68682-003-10 [68682000310]

bexarotene CAPSULE, LIQUID FILLED
Marketing CategoryNDA authorized generic
Application NumberNDA021055
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2015-12-17

Drug Details

Active Ingredients

IngredientStrength
BEXAROTENE75 mg/1

OpenFDA Data

SPL SET ID:7945daa3-b607-48c3-a94f-f3a28b033dad
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 308725
  • Pharmacological Class

    • Retinoid [EPC]
    • Retinoids [CS]

    NDC Crossover Matching brand name "bexarotene" or generic name "Bexarotene"

    NDCBrand NameGeneric Name
    0054-0399Bexarotenebexarotene
    0378-6955BexaroteneBexarotene
    0591-2832bexarotenebexarotene
    0832-0285BexaroteneBexarotene
    42292-007BexaroteneBexarotene
    43975-315BexaroteneBexarotene
    68682-002bexarotenebexarotene
    68682-003bexarotenebexarotene
    69238-1250BexaroteneBexarotene
    69238-2088BexaroteneBexarotene
    0187-5525Targretinbexarotene
    0187-5526Targretinbexarotene

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.